Monoclonal antibody · Antagonist of neonatal Fc receptor (FCGRT) · developed by Immunovant Sciences GmbH
Imeroprubart is a human monoclonal antibody that binds the neonatal Fc receptor (FcRn) at the IgG binding site, preventing FcRn from interacting with serum IgG. This blocks FcRn-mediated IgG rescue, leading to IgG degradation. It is being studied in chronic inflammatory demyelinating polyneuropathy and generalized myasthenia gravis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07039916 | Phase 3 | Generalized Myasthenia Gravis | Recruiting | IMVT |
| NCT07032662 | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | IMVT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Inflammatory Demyelinating PolyneuropathyGeneralized Myasthenia Gravis
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMVT page.
See IMVT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMVT catalysts and pipeline →